KAZIA THERAPEUTICS LTD - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of September 2026 for Kazia Therapeutics Limited, a foreign private issuer. The filing announces a corporate administrative change regarding the company's American Depositary Receipt (ADR) program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is non-financial in nature and focuses solely on the appointment of a new depositary bank.
Material Changes
- Depositary Change: On September 18, 2026, the Company appointed JPMorgan Chase Bank, N.A. as the sole depositary for its ADR program, replacing The Bank of New York Mellon.
- Deposit Agreement: A Second Amended and Restated Deposit Agreement was executed. JPMorgan will issue American Depositary Shares (ADSs), with each ADS representing 500 ordinary shares.
- Trading Status: ADSs will continue to trade on The Nasdaq Capital Market under the symbol "KZIA."
- Investor Impact: The transition is expected to be seamless. Existing ADS holders do not need to take any action and will continue to hold their positions without interruption.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document notes that JPMorgan has filed a Registration Statement on Form F-6 with the SEC in connection with the new ADR program.
Key Facts for Investor Verification
- Confirm the effective date of the depositary transition from BNY Mellon to JPMorgan.
- Verify that the ADS ratio remains at 1 ADS for 500 ordinary shares.
- Ensure no action is required from existing shareholders during the transition.
- Check the status of the Form F-6 registration filed by JPMorgan.